Related Experiment Video
Updated: Aug 8, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Control of microglial neurotoxicity by the fractalkine receptor
Astrid E Cardona1, Erik P Pioro, Margaret E Sasse
1Neuroinflammation Research Center and Department of Neurosciences, Lerner Research Institute, Cleveland, Ohio 44195, USA.
Abstract:
Microglia, the resident inflammatory cells of the CNS, are the only CNS cells that express the fractalkine receptor (CX3CR1). Using three different in vivo models, we show that CX3CR1 deficiency dysregulates microglial responses, resulting in neurotoxicity. Following peripheral lipopolysaccharide injections, Cx3cr1-/- mice showed cell-autonomous microglial neurotoxicity. In a toxic model of Parkinson disease and a transgenic model of amyotrophic lateral sclerosis, Cx3cr1-/- mice showed more extensive neuronal cell loss than Cx3cr1+ littermate controls. Augmenting CX3CR1 signaling may protect against microglial neurotoxicity, whereas CNS penetration by pharmaceutical CX3CR1 antagonists could increase neuronal vulnerability.
Insights
CX3CR1 deficiency in microglia, the CNS
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Microglia are the central nervous system's (CNS) resident immune cells.
- Microglia are unique in expressing the fractalkine receptor (CX3CR1).
Purpose of the Study:
- To investigate the role of CX3CR1 in microglial function and neurotoxicity.
- To determine the impact of CX3CR1 deficiency on neuronal health in vivo.
Main Methods:
- Utilized three distinct in vivo models of neurological conditions.
- Employed CX3CR1-deficient (Cx3cr1-/-) mice and wild-type littermate controls (Cx3cr1+).
- Administered peripheral lipopolysaccharide and utilized toxic models of Parkinson disease and amyotrophic lateral sclerosis.
Main Results:
- CX3CR1 deficiency led to dysregulated microglial responses and cell-autonomous neurotoxicity.
- Cx3cr1-/- mice exhibited exacerbated neuronal cell loss in Parkinson disease and ALS models.
- Lack of CX3CR1 signaling increased microglial-induced neuronal damage.
Conclusions:
- CX3CR1 signaling is crucial for regulating microglial responses and preventing neurotoxicity.
- Augmenting CX3CR1 signaling may offer neuroprotective benefits.
- Pharmaceutical antagonists targeting CX3CR1 within the CNS could heighten neuronal vulnerability.
